Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega-3 polyunsaturated fatty acid ethyl esters

2013 ◽  
Vol 8 (3) ◽  
pp. 329-344 ◽  
Author(s):  
Julian P Halcox
Keyword(s):  
Cardiovascular Risk ◽  
Fatty Acid ◽  
Statin Therapy ◽  
Polyunsaturated Fatty Acid ◽  
Potential Role ◽  
Fatty Acid Ethyl Esters ◽  
Ethyl Esters ◽  
Omega 3 ◽  
Lipid Management

Breast Cancer Genetic and Molecular Subtype Impacts Response to Omega-3 Fatty Acid Ethyl Esters

2016 ◽  
Vol 68 (6) ◽  
pp. 1021-1033 ◽  
Author(s):  
Ching Hui Chen ◽  
Carol Fabian ◽  
Stephen Hursting ◽  
Linda A. deGraffenried
Keyword(s):  
Breast Cancer ◽  
Fatty Acid ◽  
Molecular Subtype ◽  
Fatty Acid Ethyl Esters ◽  
Ethyl Esters ◽  
Omega 3 ◽  
Cancer Genetic ◽  
Omega 3 Fatty Acid

scholarly journals Patient with Hypertriglyceridemia, Type 2 Diabetes, and Chronic Kidney Disease Treated with Atorvastatin and Omega-3 Fatty Acid Ethyl Esters

2012 ◽  
Vol 6 (1) ◽  
pp. 122-125 ◽  
Author(s):  
Vasilios G Athyros ◽  
Dimitri P Mikhailidis
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Fatty Acid ◽  
Kidney Disease ◽  
Fatty Acid Ethyl Esters ◽  
Ethyl Esters ◽  
Omega 3 ◽  
Omega 3 Fatty Acid ◽  
Mixed Hyperlipidemia

This is a case report that describes a 67-year-old woman with mixed hyperlipidemia and diabetic nephropathy. She was initially prescribed a combination of simvastatin plus gemfibrozil by her general practitioner (GP). When referred to our cardiovascular unit, we further diagnosed the patient to have mixed hyperlipidemia and rhabdomyolysis. Because of concerns with her chronic kidney disease (CKD), we temporarily stopped all her drug treatments and started insulin treatment for her type 2 diabetes (T2D). A month later when her T2D was stabilised, we prescribed atorvastatin and an omega-3 fatty acid ethyl ester supplement to treat her hypertriglyceridemia. Within two months her blood lipids were within the recommended range. In patients with stage 3–5 CKD, it is not advisable to prescribe the fibrate gemfibrozil, particularly in combination with a statin that is metabolised predominantly in the kidneys. To minimise adverse events without compromise on efficacy, we used a combination of omega-3 fatty acid ethyl esters, which are not metabolised in the kidneys, with a statin that is minimally metabolised in the kidneys for the treatment of her hyperlipidemia.

Sign in / Sign up

Export Citation Format

Share Document